RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000025.xml
PDF herunterladen
CC BY-NC-ND 4.0 · Horm Metab Res 2021; 53(01): 9-15
DOI: 10.1055/a-1300-2550
DOI: 10.1055/a-1300-2550
Review
The Role of Glucocorticoids in the Management of COVID-19
Funding Information: This work was supported by funds from the Deutsche Forschungsgemeinschaft (SFB-TRR 205 to V.I.A. & HE 8391/1–1 to H.H.).
Abstract
Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19.
Publikationsverlauf
Eingereicht: 12. Oktober 2020
Angenommen nach Revision: 14. Oktober 2020
Artikel online veröffentlicht:
18. November 2020
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395: 507-513
- 2 Lu R, Zhao X, Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565-574
- 3 Fan E, Beitler JR, Brochard L. et al. COVID-19-associated acute respiratory distress syndrome: Is a different approach to management warranted?. Lancet Respir Med 2020; 8: 816-821
- 4 Hussman JP. Cellular and Molecular Pathways of COVID-19 and potential points of therapeutic intervention. Front Pharmacol 2020; 11: 1169
- 5 Shah A, Donovan K, McHugh A. et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: A multicentre observational study. Crit Care 2020; 24: 561
- 6 Group WHOREAfC-TW Sterne JAC, Murthy S. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A Meta-analysis. JAMA 2020; 324: 1330-1341
- 7 Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol 2019; 10: 1545
- 8 Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol 2017; 17: 233-247
- 9 Kanczkowski W, Alexaki VI, Tran N. et al. Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation. Proc Natl Acad Sci USA 2013; 110: 14801-14806
- 10 Vandewalle J, Libert C. Glucocorticoids in Sepsis: To Be or Not to Be. Front Immunol 2020; 11: 1318
- 11 Petta I, Dejager L, Ballegeer M. et al. The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases. Microbiol Mol Biol Rev 2016; 80: 495-522
- 12 Lim HW, Uhlenhaut NH, Rauch A. et al. Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. Genome Res 2015; 25: 836-844
- 13 Hudson WH, Youn C, Ortlund EA. The structural basis of direct glucocorticoid-mediated transrepression. Nat Struct Mol Biol 2013; 20: 53-58
- 14 Widen C, Gustafsson JA, Wikstrom AC. Cytosolic glucocorticoid receptor interaction with nuclear factor-kappa B proteins in rat liver cells. Biochem J 2003; 373: 211-220
- 15 Berrebi D, Bruscoli S, Cohen N. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 2003; 101: 729-738
- 16 Panettieri RA, Schaafsma D, Amrani Y. et al. Non-genomic effects of glucocorticoids: An updated view. Trends Pharmacol Sci 2019; 40: 38-49
- 17 Lowenberg M, Verhaar AP, Bilderbeek J. et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN 2006; 7: 1023-1029
- 18 Jiang CL, Liu L, Tasker JG. Why do we need nongenomic glucocorticoid mechanisms?. Front Neuroendocrinol 2014; 35: 72-75
- 19 Busillo JM, Cidlowski JA. The five Rs of glucocorticoid action during inflammation: Ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab 2013; 24: 109-119
- 20 Lim HY, Muller N, Herold MJ. et al. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007; 122: 47-53
- 21 Dhabhar FS, McEwen BS. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci USA 1999; 96: 1059-1064
- 22 Quatrini L, Ugolini S. New insights into the cell- and tissue-specificity of glucocorticoid actions. Cell Mol Immunol 2020; 1-10
- 23 Miyata M, Lee JY, Susuki-Miyata S. et al. Glucocorticoids suppress inflammation via the upregulation of negative regulator IRAK-M. Nat Commun 2015; 6: 6062
- 24 Bhattacharyya S, Brown DE, Brewer JA. et al. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 2007; 109: 4313-4319
- 25 Visser J, van Boxel-Dezaire A, Methorst D. et al. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 1998; 91: 4255-4264
- 26 Lee SH, Soyoola E, Chanmugam P. et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934-25938
- 27 Yang N, Zhang W, Shi XM. Glucocorticoid-induced leucine zipper (GILZ) mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 expression. J Cell Biochem 2008; 103: 1760-1771
- 28 Mitroulis I, Alexaki VI, Kourtzelis I. et al. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther 2015; 147: 123-135
- 29 Zielinska KA, Van Moortel L, Opdenakker G. et al. Endothelial response to glucocorticoids in inflammatory diseases. Front Immunol 2016; 7: 592
- 30 Ehrchen J, Steinmuller L, Barczyk K. et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007; 109: 1265-1274
- 31 Mozo L, Suarez A, Gutierrez C. Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes. Clin Exp Allergy 2004; 34: 406-412
- 32 Tu GW, Shi Y, Zheng YJ. et al. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. J Transl Med 2017; 15: 181
- 33 Meers GK, Bohnenberger H, Reichardt HM. et al. Impaired resolution of DSS-induced colitis in mice lacking the glucocorticoid receptor in myeloid cells. PLoS One 2018; 13: e0190846
- 34 Vallelian F, Schaer CA, Kaempfer T. et al. Glucocorticoid treatment skews human monocyte differentiation into a hemoglobin-clearance phenotype with enhanced heme-iron recycling and antioxidant capacity. Blood 2010; 116: 5347-5356
- 35 van der Goes A, Hoekstra K, van den Berg TK. et al. Dexamethasone promotes phagocytosis and bacterial killing by human monocytes/macrophages in vitro. J Leukoc Biol 2000; 67: 801-807
- 36 Cao Y, Bender IK, Konstantinidis AK. et al. Glucocorticoid receptor translational isoforms underlie maturational stage-specific glucocorticoid sensitivities of dendritic cells in mice and humans. Blood 2013; 121: 1553-1562
- 37 Kim KD, Choe YK, Choe IS. et al. Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J Leukoc Biol 2001; 69: 426-434
- 38 Wang D, Muller N, McPherson KG. et al. Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J Immunol 2006; 176: 1695-1702
- 39 Lowenberg M, Verhaar AP, van den Brink GR. et al. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 2007; 13: 158-163
- 40 Bereshchenko O, Coppo M, Bruscoli S. et al. GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-beta signaling. Cell Rep 2014; 7: 464-475
- 41 Galon J, Franchimont D, Hiroi N. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002; 16: 61-71
- 42 Alan I, Alan B. Side effects of glucocorticoids. Pharmacokinetics and adverse effects of drugs - mechanisms and risks Factors 2017;
- 43 Huscher D, Thiele K, Gromnica-Ihle E. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119-1124
- 44 Nicolaides NC, Pavlaki AN, Maria Alexandra MA. et al. Endotext. South Dartmouth, MA: 2000
- 45 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280 e278
- 46 Shereen MA, Khan S, Kazmi A. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-98
- 47 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
- 48 Qin C, Zhou L, Hu Z. et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71: 762-768
- 49 Blanco-Melo D, Nilsson-Payant BE, Liu WC. et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 2020; 181: 1036-1045 e1039
- 50 Fox SE, Akmatbekov A, Harbert JL. et al. Pulmonary and cardiac pathology in African American patients with COVID-19: An autopsy series from New Orleans. Lancet. Respir Med 2020; 8: 681-686
- 51 Polycarpou A, Howard M, Farrar CA. et al. Rationale for targeting complement in COVID-19. EMBO Mol Med 2020; 12: e12642
- 52 Gralinski LE, Sheahan TP, Morrison TE. et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio 2018; 9: e01753-18
- 53 Risitano AM, Mastellos DC, Huber-Lang M. et al. Complement as a target in COVID-19?. Nat Rev Immunol 2020; 20: 343-344
- 54 Java A, Apicelli AJ, Liszewski MK. et al. The complement system in COVID-19: friend and foe?. JCI Insight 2020; 5: e140711
- 55 Risitano AM, Mastellos DC, Huber-Lang M. et al. Author Correction: Complement as a target in COVID-19?. Nat Rev Immunol 2020; 20: 448
- 56 Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet. Respir Med 2020; 8: 420-422
- 57 Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020; 506: 145-148
- 58 Liu F, Ji C, Luo J. et al. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. Sci Rep 2020; 10: 13689
- 59 Selvaraj V, Dapaah-Afriyie K, Finn A. et al. Short-Term Dexamethasone in Sars-CoV-2 Patients. R I Med J (2013) 2020; 103: 39-43
- 60
Bellani G,
Laffey JG,
Pham T.
Epidemiology, patterns of care, and mortality for patients with acute respiratory
distress syndrome in intensive care units in 50 countries. JAMA 2016; 315: 788-800
MissingFormLabel
- 61 Acute Respiratory Distress Syndrome N, Brower RG, Matthay MA. et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301-1308
- 62
Guerin C,
Reignier J,
Richard JC.
Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013;
368: 2159-2168
MissingFormLabel
- 63 Agarwal R, Nath A, Aggarwal AN. et al. Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 2007; 12: 585-590
- 64 Meduri GU, Marik PE, Chrousos GP. et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34: 61-69
- 65 Zayed Y, Barbarawi M, Ismail E. et al. Use of glucocorticoids in patients with acute respiratory distress syndrome: A meta-analysis and trial sequential analysis. J Intensive Care 2020; 8: 43
- 66 Zhao Q, Shi JX, Hu R. et al. Effect of glucocorticoids on mortality in patients with acute respiratory distress syndrome: A meta-analysis. Exp Ther Med 2019; 18: 4913-4920
- 67 Arabi YM, Mandourah Y, Al-Hameed F. et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 2018; 197: 757-767
- 68 Lansbury LE, Rodrigo C, Leonardi-Bee J. et al. Corticosteroids as adjunctive therapy in the treatment of influenza: An updated cochrane systematic review and meta-analysis. Crit Care Med 2020; 48: e98-e106
- 69 Rostaing L, Malvezzi P. Steroid-based therapy and risk of infectious complications. PLoS Med 2016; 13: e1002025
- 70 Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 2016; 13: e1002024
- 71 Normand ST. The RECOVERY Platform. N Engl J Med 2020;
- 72 Group RC, Horby P, Lim WS. et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med 2020;
- 73 Critchley JA, Carey IM, Harris T. et al. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care 2018; 41: 2127-2135
- 74 Rao Kondapally Seshasai S, Kaptoge S, Thompson A. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841
- 75 Yang JK, Feng Y, Yuan MY. et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006; 23: 623-628
- 76 Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R. et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect 2018; 147: 1-5
- 77
Zhou F,
Yu T,
Du R.
et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19
in Wuhan, China: A retrospective cohort study. Lancet 2020; 395: 1054-1062
MissingFormLabel
- 78 Barron E, Bakhai C, Kar P. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol 2020; 8: 813-822
- 79 Holman N, Knighton P, Kar P. et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol 2020; 8: 823-833
- 80 Zhu L, She ZG, Cheng X. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 31: 1068-1077 e1063
- 81 Kalligeros M, Shehadeh F, Mylona EK. et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring) 2020; 28: 1200-1204
- 82 Hamer M, Gale CR, Kivimaki M. et al. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. Proc Natl Acad Sci USA 2020; 117: 21011-21013
- 83 Bornstein SR, Rubino F, Khunti K. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020; 8: 546-550
- 84 Erener S. Diabetes, infection risk and COVID-19. Mol Metab 2020; 39: 101044
- 85 Feldman-Billard S, Lissak B, Kassaei R. et al. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology 2005; 112: 511-515
- 86 Reynolds RM, Labad J, Sears AV. et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: The Edinburgh Type 2 Diabetes Study. Eur J Endocrinol 2012; 166: 861-868
- 87 Fardet L, Flahault A, Kettaneh A. et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007; 157: 142-148
- 88 Sato A, Funder JW, Okubo M. et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995; 8: 823-828
- 89 Curtis JR, Westfall AO. Allison. et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55: 420-426
- 90 Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770
- 91 Souverein PC, Berard A, Van Staa TP. et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859-865